Journal: Nature Communications

Article Title: T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2 + solid and hematologic cancers

doi: 10.1038/s41467-026-69621-8

Figure Lengend Snippet: a Schematic presentation showing the recognition of DKK1-A2 CAR-T cells and DKK1-A2 expressing tumor cells. b Schematic presentation showing DKK1-A2 and CD19 CAR constructs. c Percentage of CAR expressing T cells determined as eGFP positive T cells by flow cytometry analysis. d Expression of DKK1, HLA-A2 or DKK1-A2 complex by JeKo-1, Daudi, U266, KMS-26, CFPAC-1, PANC-1, NCI-H441 or MDA-MB-231 tumor cell lines determined by flow cytometry. e CAR-T cell proliferation measured by dilution of Celltrace Violet analyzed by flow cytometry. CAR-T cells were stained with Celltrace Violet and co-cultured with JeKo-1, Daudi, U266 or CFPAC-1 tumor cells at an E:T ratio of 1:1 for 72 h. f Cytotoxicity of CAR-T cells determined by luciferase reporter assay. CAR-T cells were co-cultured with Luc-transduced JeKo-1, Daudi, U266, KMS-26, CFPAC-1, PANC-1, NCI-H441, or MDA-MB-231 tumor cells at indicated E:T ratios for 12 h. n = 3, technical replicates. g , h Percentages of IFN-γ and TNF-α producing CD4 + or CD8 + CAR-T cells determined by intracellular cytokine staining. CAR-T cells were co-cultured with JeKo-1, Daudi, MM.1S-A2, KMS-12-BM-A2, CFPAC-1 or PANC-1 tumor cells at an E:T ratio of 1:1 overnight. In the experiments, CD19 CAR-T cells were used as a control. n = 3, technical replicates. Data shown as mean ± SEM. Source data are provided as a file.

Article Snippet: Human mantle cell lymphoma cell line JeKo-1, Burkitt’s lymphoma cell line Daudi, MM cell lines U266, KMS-26, ARP-1, KMS-11, KMS-12-BM, and MM.1S, PDAC cell lines CFPAC-1, PANC-1, MIA PaCa-2, and PL45, NSCLC cell lines NCI-H441 and NCI-H266, and TNBC cell lines MDA-MB-231 and MDA-MB-468 were purchased from American Type Culture Collection or obtained from Arkansas Cancer Research Center.

Techniques: Expressing, Construct, Flow Cytometry, Staining, Cell Culture, Luciferase, Reporter Assay, Control

Journal: Nature Communications

Article Title: T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2 + solid and hematologic cancers

doi: 10.1038/s41467-026-69621-8

Figure Lengend Snippet: a , b mC2 or hC2 CAR-T cells were generated from 4 healthy donors. CCR7 and CD45RO expression on CAR-T cells was analyzed by flow cytometry, and c , d mC2 or hC2 CAR-T cells were generated from 4 healthy donors and then co-cultured with JeKo-1 tumor cells for 24 h. CCR7 and CD45RO expressions on CAR-T cells were analyzed by flow cytometry. Tn/Tscm: CCR7 + CD45RO – , Tcm: CCR7 + CD45RO + , Tem: CCR7 – CD45RO + , and Temra: CCR7 – CD45RO – . Percentage (%) was defined as the proportion of memory phenotypes relative to eGFP + CAR-T cells. n = 4, biological replicates. Two-tailed Student’s t -test was used. e – g Percentages of IFN-γ, TNF-α and Granzyme B producing CD4 + or CD8 + CAR-T cells analyzed by intracellular cytokine staining. mC2 and hC2 CAR-T cells were co-cultured with JeKo-1 tumor cells overnight. n = 4, biological replicates. Two-tailed Student’s t -test was used. h – j Percentages of IFN-γ, TNF-α, and Granzyme B producing CD4 + or CD8 + CAR-T cells analyzed by intracellular cytokine staining. mC2 and hC2 CAR-T cells were co-cultured with JeKo-1 tumor cells overnight, followed by JeKo-1 tumor cells re-challenge overnight again. n = 4, biological replicates. Two-tailed Student’s t -test was used. k Schema of JeKo-1-bearing NSG mice treated with mC2 or hC2 CAR-T cells, followed by JeKo-1 re-challenge controlled with naïve mice, l Tumor volume measured weekly post tumor cell re-challenge. Two-way ANOVA was used, m Survival of JeKo-1-bearing NSG mice. Log-rank test was used, and n Percentages of CAR-T cells in blood, lymph node, and spleen in JeKo-1-bearing NSG mice identified as GFP expression by flow cytometry at endpoint. Ctrl, n = 5; mC2 CAR-T, n = 5; hC2 CAR-T, n = 5; biological replicates. Two-tailed Student’s t -test was used. Data shown as mean ± SEM. Source data are provided as a file.

Article Snippet: Human mantle cell lymphoma cell line JeKo-1, Burkitt’s lymphoma cell line Daudi, MM cell lines U266, KMS-26, ARP-1, KMS-11, KMS-12-BM, and MM.1S, PDAC cell lines CFPAC-1, PANC-1, MIA PaCa-2, and PL45, NSCLC cell lines NCI-H441 and NCI-H266, and TNBC cell lines MDA-MB-231 and MDA-MB-468 were purchased from American Type Culture Collection or obtained from Arkansas Cancer Research Center.

Techniques: Generated, Expressing, Flow Cytometry, Cell Culture, Two Tailed Test, Staining

Journal: Nature Communications

Article Title: T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2 + solid and hematologic cancers

doi: 10.1038/s41467-026-69621-8

Figure Lengend Snippet: a Immunohistochemistry staining of human normal tissue microarray containing 35 different types of normal tissues (including Marker) from three HLA-A2 positive donors stained with DKK1, HLA-A2 and DKK1-A2 complex. b , c Levels of secreted human IFN-γ and IL-6 in co-culture of CAR-T cells with autologous monocytes and JeKo-1 tumor cells for 24 h determined by ELISA. n = 5, technical replicates. One-way ANOVA was used. d , e Levels of secreted human IFN-γ and murine IL-6 in the peritoneal lavage fluid of JeKo-1 bearing mice treated with intraperitoneally infused an excessive dose of CAR-T cells determined 3 days post CAR-T cell infusion. n = 5, biological replicates. One-way ANOVA was used. f Body weight change of SCID mice transferred with the excessive dose of CAR-T cells monitored every 24 h. n = 5, biological replicates. Two-way ANOVA was used. g – i Numbers of immune cell populations in blood, spleen and bone marrow of hDKK1-A2 mice treated with murine DKK1-CAR-T cells analyzed by flow cytometry. n = 5, biological replicates. One-way ANOVA was used. In most experiments, CD19 CAR-T cells were used as a control. Data shown as mean ± SEM. Source data are provided as a file.

Article Snippet: Human mantle cell lymphoma cell line JeKo-1, Burkitt’s lymphoma cell line Daudi, MM cell lines U266, KMS-26, ARP-1, KMS-11, KMS-12-BM, and MM.1S, PDAC cell lines CFPAC-1, PANC-1, MIA PaCa-2, and PL45, NSCLC cell lines NCI-H441 and NCI-H266, and TNBC cell lines MDA-MB-231 and MDA-MB-468 were purchased from American Type Culture Collection or obtained from Arkansas Cancer Research Center.

Techniques: Immunohistochemistry, Staining, Microarray, Marker, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Control

Journal: bioRxiv

Article Title: Systematic fusion transcript discovery in mantle cell lymphoma using long-read sequencing

doi: 10.64898/2026.01.16.699780

Figure Lengend Snippet: a . RBM15 Schematic representation of the human RBM15 transcript and the relative locations of the antisense RBM15-AS and LAMTOR5-AS transcripts. b . Iso-Seq. reads showing the sequence at the 5’end and the sequence at the 3’end of the fusion mapping to RBM15 and LAMTOR5-AS respectively. Underlined is a potential polyadenylation signal within RBM15. c. Ethidium Bromide Agarose gel showing the PCR products obtained using primers in the ORF of RBM15 (top panel) and two different sets of primers (set one and set 2) spanning the RBM15 and the LAMTOR5-AS regions. Results of western blot analysis of cell lysates from d . mantle cell lymphoma cell lines and e . other cell lines using antibodies targeting RBM15 with GAPDH as the loading control. f . MTT assay results for different cell lines treated with delivery vehicle (DMSO) or JTE-607 for 72 hours normalized to DMSO control (n=6, shown is the mean and SD). MDA-MB-231 qRT-PCR results showing fold change in expression of the RBM15::LAMTOR5 fusion transcript after g . 72 hours treatment with JTE-607 over DMSO treated samples after normalizing to GAPDH and h . 48 hours after siRNA with CPSF73 over control siRNA. For g and h , shown is the mean and SD (n=3), with p-values calculated from a two tailed t-test).

Article Snippet: With the exception of the Granta-519 cell line, all the mantle cell lymphoma cell lines (Jeko-1, Mino, Z-138 and Rec-1) and other cell lines, Hela, LN229, MDA-MB-231, Ovcar-3 and SH-SY5Y) and CD19+ B-cells were purchased from ATCC ( Manassas, VA).

Techniques: Sequencing, Agarose Gel Electrophoresis, Western Blot, Control, MTT Assay, Quantitative RT-PCR, Expressing, Two Tailed Test